Pegram M - Search Results

1

Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer.

Araki K, Saji S, Gallas M, Pegram M, Sasaki Y. Araki K, et al. Among authors: pegram m. Breast Cancer. 2012 Apr;19(2):95-103. doi: 10.1007/s12282-011-0296-z. Epub 2011 Aug 24. Breast Cancer. 2012. PMID: 21863310 Review.

2

Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.

Pegram MD, O'Callaghan C. Pegram MD, et al. Clin Breast Cancer. 2001 Oct;2 Suppl 1:S15-9. doi: 10.3816/cbc.2001.s.003. Clin Breast Cancer. 2001. PMID: 11970740 Review.

3

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.

Yeon CH, Pegram MD. Yeon CH, et al. Invest New Drugs. 2005 Oct;23(5):391-409. doi: 10.1007/s10637-005-2899-8. Invest New Drugs. 2005. PMID: 16133791 Review.

4

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Konecny GE, et al. Among authors: pegram md. Cancer Res. 2006 Feb 1;66(3):1630-9. doi: 10.1158/0008-5472.CAN-05-1182. Cancer Res. 2006. PMID: 16452222

5

Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.

Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B. Jerome L, et al. Among authors: pegram m. Cancer Res. 2006 Jul 15;66(14):7245-52. doi: 10.1158/0008-5472.CAN-05-3555. Cancer Res. 2006. PMID: 16849573

6

Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?

Pegram M. Pegram M. Clin Breast Cancer. 2008 Mar;8 Suppl 3:S121-30. doi: 10.3816/cbc.2008.s.008. Clin Breast Cancer. 2008. PMID: 18777951 Review.

7

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, Forster JK, Rubin SD, Stein SH, Burstein HJ. Blackwell KL, et al. Among authors: pegram md. Ann Oncol. 2009 Jun;20(6):1026-31. doi: 10.1093/annonc/mdn759. Epub 2009 Jan 29. Ann Oncol. 2009. PMID: 19179558 Free article. Clinical Trial.

8

Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer.

Pal SK, Childs BH, Pegram M. Pal SK, et al. Among authors: pegram m. Breast Cancer Res Treat. 2010 Jan;119(1):25-32. doi: 10.1007/s10549-009-0567-y. Breast Cancer Res Treat. 2010. PMID: 19795206 Review.

9

Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?

Araki K, Pegram M. Araki K, et al. Among authors: pegram m. Breast Cancer Res Treat. 2011 Jun;127(2):589-90. doi: 10.1007/s10549-009-0543-6. Epub 2009 Oct 16. Breast Cancer Res Treat. 2011. PMID: 19834800 No abstract available.

10

Triple negative breast cancer: unmet medical needs.

Pal SK, Childs BH, Pegram M. Pal SK, et al. Among authors: pegram m. Breast Cancer Res Treat. 2011 Feb;125(3):627-36. doi: 10.1007/s10549-010-1293-1. Epub 2010 Dec 15. Breast Cancer Res Treat. 2011. PMID: 21161370 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

170 results

Search Page

Filters